Travere Therapeutics, Inc. (TVTX)
| Market Cap | 4.63B +43.6% |
| Revenue (ttm) | 651.03M +49.4% |
| Net Income | -121.51M |
| EPS | -1.31 |
| Shares Out | 95.99M |
| PE Ratio | n/a |
| Forward PE | 10.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 448,196 |
| Open | 48.09 |
| Previous Close | 48.30 |
| Day's Range | 47.60 - 49.35 |
| 52-Week Range | 22.59 - 68.73 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 73.43 (+52.34%) |
| Earnings Date | Nov 2, 2026 |
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin... [Read more]
Financial Performance
In 2025, Travere Therapeutics's revenue was $490.73 million, an increase of 110.45% compared to the previous year's $233.18 million. Losses were -$25.55 million, -92.06% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $73.43, which is an increase of 52.34% from the latest price.
News
Travere Therapeutics Transcript: Jefferies Global Healthcare Conference
Q3 delivered 1,932 FILSPARI patient start forms and $200M in net revenue, while management cited early penetration across IgAN and FSGS. The $3B annual sales target by 2033 is supported by broad kidney-disease opportunities, extended patents and pipeline progress.
Travere Therapeutics Transcript: UBS Global Biopharma Conference 2026
FILSPARI sales rose ~120% YoY in Q3, with early FSGS uptake supporting a goal of $3B net product sales by 2033. Pegtibatinase phase III data are expected in H2 2027, while civorebrutinib is advancing toward late-stage development.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equit...
Travere Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
3Q revenue was $200M, with 1,932 new patient start forms and continued FILSPARI demand across IgAN and FSGS. Pipeline priorities include a 2026 civorebrutinib IND and Phase III pegtibatinase development, with management citing a path to profitability.
Travere Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
FILSPARI delivered $200 million in Q3 net revenue, with broad FSGS uptake and continued IgAN prescribing momentum. Pegtibatinase pivotal data are expected in H2 next year, while civorebrutinib IND filing is planned by year-end.
Travere Therapeutics price target lowered to $86 from $90 at JPMorgan
JPMorgan lowered the firm’s price target on Travere Therapeutics (TVTX) to $86 from $90 and keeps an Overweight rating on the shares.
Travere Therapeutics price target lowered to $78 from $89 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Travere Therapeutics (TVTX) to $78 from $89 and keeps a Buy rating on the shares.
Travere Therapeutics price target raised to $72 from $70 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $72 from $70 and keeps a Buy rating on the shares. The firm updated its model…
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Globa...
Buy Travere Therapeutics on weakness, says Cantor Fitzgerald
Travere Therapeutics (TVTX)’ Q3 Filspari patient starts declined 4% sequentially to 1,932, below expectations for growth, but revenue beat estimates by more than 10% even excluding one-offs, Cantor Fi...
Travere Therapeutics Earnings Call Transcript: Q3 2026
Q3 FILSPARI sales reached $200.2 million, up approximately 120% YoY, and management reaffirmed the $3 billion 2033 sales ambition. Pipeline progress includes HARMONY results targeted for H2 2027 and a civorebrutinib IND expected by year-end.
Travere Therapeutics Earnings release: Q3 2026
Travere Therapeutics released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Travere Therapeutics Quarterly report: Q3 2026
Travere Therapeutics has published its Q3 2026 quarterly earnings report on November 2, 2026.
Travere Therapeutics Slides: Q3 2026
Travere Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Travere Therapeutics reports Q3 EPS (31c), consensus 42c
Reports Q3 revenue $224.6M, consensus $195.3M. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we…
Travere Therapeutics Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our bu...
Travere Therapeutics to Report Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the ...
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may mod...
Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week
Travere Therapeutics (TVTX) will share nine new data presentations, including five oral presentations, at the American Society of Nephrology Kidney Week 2026 in Denver, CO, October 21-25. The presenta...
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Socie...
Travere Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
FILSPARI demand is strong across IgAN and FSGS, with broad physician uptake and expected mid-20% gross-to-net for the balance of the year. Pipeline priorities include civorebrutinib and phase III pegtibatinase, with topline HCU data expected in H2 2027.
Travere Therapeutics price target raised to $89 from $75 at Guggenheim
Guggenheim raised the firm’s price target on Travere Therapeutics (TVTX) to $89 from $75 and keeps a Buy rating on the shares after the company announced that the U.S. Patent…
Travere Therapeutics receives notice of allowance for FILSPARI patent
Travere Therapeutics (TVTX) announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide Compounds...
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Applicatio...
Travere Therapeutics CEO Dube to step down
Travere Therapeutics (TVTX) announced that Eric Dube, Ph.D., has made the decision to step down as president and chief executive officer to “focus on his health and family.” The company’s…